Ayala Pharmaceuticals, Inc. (ADXS) Research
Ayala Pharmaceuticals, Inc., a clinical-stage oncology firm, focuses on developing and commercializing small molecule therapies for individuals battling rare tumors and aggressive cancers. Its primary drug candidates currently in development include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an innovative, proprietary anti-metabolite designed for first-line treatment in acute myeloid leukemia patients who are considered unfit. The company is headquartered in Wilmington, Delaware.
Market snapshot
- Symbol
- ADXS
- Price
- $0.60
- Day change
- 0.00%
- Market cap
- $25.7M
- P/E ratio
- -0.08x
- 52-week range
- 0.0011-0.801
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Recent insider activity
- Israel Biotech Fund I, L.P. — M-Exempt (2250000 shares) on 2024-03-01
- Israel Biotech Fund I, L.P. — M-Exempt (1500000 shares) on 2024-03-01
- Israel Biotech Fund I, L.P. — M-Exempt (3750000 shares) on 2024-03-01
- Israel Biotech Fund I, L.P. — M-Exempt (2250000 shares) on 2024-03-01
- Israel Biotech Fund I, L.P. — M-Exempt (1500000 shares) on 2024-03-01
Open Ayala Pharmaceuticals, Inc. (ADXS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.